U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C15H14FN3O3
Molecular Weight 303.2884
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FLUMAZENIL

SMILES

CCOC(=O)C1=C2CN(C)C(=O)C3=CC(F)=CC=C3N2C=N1

InChI

InChIKey=OFBIFZUFASYYRE-UHFFFAOYSA-N
InChI=1S/C15H14FN3O3/c1-3-22-15(21)13-12-7-18(2)14(20)10-6-9(16)4-5-11(10)19(12)8-17-13/h4-6,8H,3,7H2,1-2H3

HIDE SMILES / InChI
Molecular Formula C15H14FN3O3
Molecular Weight 303.2884
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/cdi/flumazenil.html

Fumazenil is an imidazobenzodiazepine derivative and a potent benzodiazepine receptor antagonist that competitively inhibits the activity at the benzodiazepine recognition site on the GABA/benzodiazepine receptor complex, thereby reversing the effects of benzodiazepine on the central nervous system. Fumazenil is used for the complete or partial reversal of the sedative effects of benzodiazepines in cases where general anesthesia has been induced and/or maintained with benzodiazepines, and where sedation has been produced with benzodiazepines for diagnostic and therapeutic procedures. Also for the management of benzodiazepine overdose as an adjunct for appropriate supportive and symptomatic measures. Flumazenil went off patent in 2008 so at present generic formulations of this drug are available.

CNS Activity

Originator

Approval Year

1991
122
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
2849
Antagonist
2849
 3.3 nM [Ki]
Antagonist
2849
 148.0 nM [Ki]
Gamma-aminobutyric acid receptor subunit gamma-2
2
Target ID: P18507
Gene ID: 2566.0
Gene Symbol: GABRG2
Target Organism: Homo sapiens (Human)
Antagonist
2849
Antagonist
2849
 8.1 nM [Ki]
Antagonist
2849
 5.7 nM [Ki]
Antagonist
2849
 2.0 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Secondary
Approved
8583
FLUMAZENIL

Approved Use

Flumazenil Injection, USP is indicated for the complete or partial reversal of the sedative effects of benzodiazepines in cases where general anesthesia has been induced and/or maintained with benzodiazepines, where sedation has been produced with benzodiazepines for diagnostic and therapeutic procedures, and for the management of benzodiazepine overdose.

Launch Date

2004
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
45.9 ng/mL
EXPERIMENT
https://pdfs.semanticscholar.org/7fec/02a99fcca4c9565aa786b9ade3853eb74058.pdf
0.2 mg single, intravenous
dose: 0.2 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
FLUMAZENIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
6.98 ng/mL
EXPERIMENT
https://pdfs.semanticscholar.org/7fec/02a99fcca4c9565aa786b9ade3853eb74058.pdf
2.2 mg single, sublingual
dose: 2.2 mg
route of administration: Sublingual
experiment type: SINGLE
co-administered:
FLUMAZENIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
5.28 ng/mL
EXPERIMENT
https://pdfs.semanticscholar.org/7fec/02a99fcca4c9565aa786b9ade3853eb74058.pdf
2.2 mg single, sublingual
dose: 2.2 mg
route of administration: Sublingual
experiment type: SINGLE
co-administered:
FLUMAZENIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: HIGH-FAT
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
12.9 ng × h/mL
EXPERIMENT
https://pdfs.semanticscholar.org/7fec/02a99fcca4c9565aa786b9ade3853eb74058.pdf
0.2 mg single, intravenous
dose: 0.2 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
FLUMAZENIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
12 ng × h/mL
EXPERIMENT
https://pdfs.semanticscholar.org/7fec/02a99fcca4c9565aa786b9ade3853eb74058.pdf
2.2 mg single, sublingual
dose: 2.2 mg
route of administration: Sublingual
experiment type: SINGLE
co-administered:
FLUMAZENIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
9.1 ng × h/mL
EXPERIMENT
https://pdfs.semanticscholar.org/7fec/02a99fcca4c9565aa786b9ade3853eb74058.pdf
2.2 mg single, sublingual
dose: 2.2 mg
route of administration: Sublingual
experiment type: SINGLE
co-administered:
FLUMAZENIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: HIGH-FAT
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.18 h
EXPERIMENT
https://pdfs.semanticscholar.org/7fec/02a99fcca4c9565aa786b9ade3853eb74058.pdf
0.2 mg single, intravenous
dose: 0.2 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
FLUMAZENIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1.05 h
EXPERIMENT
https://pdfs.semanticscholar.org/7fec/02a99fcca4c9565aa786b9ade3853eb74058.pdf
2.2 mg single, sublingual
dose: 2.2 mg
route of administration: Sublingual
experiment type: SINGLE
co-administered:
FLUMAZENIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1.12 h
EXPERIMENT
https://pdfs.semanticscholar.org/7fec/02a99fcca4c9565aa786b9ade3853eb74058.pdf
2.2 mg single, sublingual
dose: 2.2 mg
route of administration: Sublingual
experiment type: SINGLE
co-administered:
FLUMAZENIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: HIGH-FAT
Doses

Doses

DosePopulationAdverse events​
3 mg single, intravenous
Highest studied dose
Dose: 3 mg
Route: intravenous
Route: single
Dose: 3 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/1647443/
unhealthy, 32-62
Health Status: unhealthy
Age Group: 32-62
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/1647443/
Sources:
https://pubmed.ncbi.nlm.nih.gov/1647443/
7.13 mg single, intravenous
Recommended
Dose: 7.13 mg
Route: intravenous
Route: single
Dose: 7.13 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/8239101/
unhealthy, 35.2 years (range: 17-75 years)
Health Status: unhealthy
Age Group: 35.2 years (range: 17-75 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/8239101/
Other AEs: Injection site pain, Agitation...
Other AEs:
Injection site pain (10.3%)
Agitation (8%)
Anxiety (3.4%)
Crying abnormal (3.4%)
Headache (3.4%)
Vomiting (3.4%)
Tachycardia (3.4%)
Dizziness (3.4%)
Nausea (2.3%)
Convulsions (1.1%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/8239101/
1 mg single, intravenous
Recommended
Dose: 1 mg
Route: intravenous
Route: single
Dose: 1 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/9695999/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9695999/
Sources:
https://pubmed.ncbi.nlm.nih.gov/9695999/
AEs

AEs

AESignificanceDosePopulation
Convulsions 1.1%
7.13 mg single, intravenous
Recommended
Dose: 7.13 mg
Route: intravenous
Route: single
Dose: 7.13 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/8239101/
unhealthy, 35.2 years (range: 17-75 years)
Health Status: unhealthy
Age Group: 35.2 years (range: 17-75 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/8239101/
Injection site pain 10.3%
7.13 mg single, intravenous
Recommended
Dose: 7.13 mg
Route: intravenous
Route: single
Dose: 7.13 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/8239101/
unhealthy, 35.2 years (range: 17-75 years)
Health Status: unhealthy
Age Group: 35.2 years (range: 17-75 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/8239101/
Nausea 2.3%
7.13 mg single, intravenous
Recommended
Dose: 7.13 mg
Route: intravenous
Route: single
Dose: 7.13 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/8239101/
unhealthy, 35.2 years (range: 17-75 years)
Health Status: unhealthy
Age Group: 35.2 years (range: 17-75 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/8239101/
Anxiety 3.4%
7.13 mg single, intravenous
Recommended
Dose: 7.13 mg
Route: intravenous
Route: single
Dose: 7.13 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/8239101/
unhealthy, 35.2 years (range: 17-75 years)
Health Status: unhealthy
Age Group: 35.2 years (range: 17-75 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/8239101/
Crying abnormal 3.4%
7.13 mg single, intravenous
Recommended
Dose: 7.13 mg
Route: intravenous
Route: single
Dose: 7.13 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/8239101/
unhealthy, 35.2 years (range: 17-75 years)
Health Status: unhealthy
Age Group: 35.2 years (range: 17-75 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/8239101/
Dizziness 3.4%
7.13 mg single, intravenous
Recommended
Dose: 7.13 mg
Route: intravenous
Route: single
Dose: 7.13 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/8239101/
unhealthy, 35.2 years (range: 17-75 years)
Health Status: unhealthy
Age Group: 35.2 years (range: 17-75 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/8239101/
Headache 3.4%
7.13 mg single, intravenous
Recommended
Dose: 7.13 mg
Route: intravenous
Route: single
Dose: 7.13 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/8239101/
unhealthy, 35.2 years (range: 17-75 years)
Health Status: unhealthy
Age Group: 35.2 years (range: 17-75 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/8239101/
Tachycardia 3.4%
7.13 mg single, intravenous
Recommended
Dose: 7.13 mg
Route: intravenous
Route: single
Dose: 7.13 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/8239101/
unhealthy, 35.2 years (range: 17-75 years)
Health Status: unhealthy
Age Group: 35.2 years (range: 17-75 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/8239101/
Vomiting 3.4%
7.13 mg single, intravenous
Recommended
Dose: 7.13 mg
Route: intravenous
Route: single
Dose: 7.13 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/8239101/
unhealthy, 35.2 years (range: 17-75 years)
Health Status: unhealthy
Age Group: 35.2 years (range: 17-75 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/8239101/
Agitation 8%
7.13 mg single, intravenous
Recommended
Dose: 7.13 mg
Route: intravenous
Route: single
Dose: 7.13 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/8239101/
unhealthy, 35.2 years (range: 17-75 years)
Health Status: unhealthy
Age Group: 35.2 years (range: 17-75 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/8239101/
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
activator
150

inducer
1087

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CES1
45

P-gp
2052
CYP2B6
669

CYP1A2
832
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP1A2
2333
 no
CYP1A2
2333
 no
CYP2B6
1160
 no
CYP2B6
1160
 no
CYP3A4
2633
 no
CYP3A4
2633
 no
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CES1
45
 yes
P-gp
2052
 yes
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:5103
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:5103
ChemicalBook
CB9208108
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB9208108
eMolecules
538442
https://www.emolecules.com/cgi-bin/more?vid=538442
MolPort
MolPort-003-666-855
https://www.molport.com/shop/molecule-link/MolPort-003-666-855
Selleck Chemicals
Flumazenil
http://www.selleckchem.com/products/Flumazenil.html
ZINC
ZINC000000001464
http://zinc15.docking.org/substances/ZINC000000001464
PubMed

PubMed

TitleDatePubMed
Binding and neuropharmacological profile of zaleplon, a novel nonbenzodiazepine sedative/hypnotic.
2002-01-02
Involvement of benzodiazepine binding sites in an antiaggressive effect by 5-HT(1A) receptor activation in isolated mice.
2001-12-07
Binding of [3H]CB 34, a selective ligand for peripheral benzodiazepine receptors, to rat brain membranes.
2001-12-07
Delayed synaptic dysfunction of association cortices in carbon monoxide intoxication.
2001-12
Dual-[11C]tracer single-acquisition positron emission tomography studies.
2001-12
Chronic benzodiazepine treatment of cells expressing recombinant GABA(A) receptors uncouples allosteric binding: studies on possible mechanisms.
2001-12
The midazolam-induced paradox phenomenon is reversible by flumazenil. Epidemiology, patient characteristics and review of the literature.
2001-12
Brain function in social anxiety disorder.
2001-12
Effect of diazepam binding inhibitor (DBI) on the fluid intake, preference and the taste reactivity in mice.
2001-11-29
[Functional imaging (PET and SPECT) in epilepsy].
2001-11-04
The negative GABA(A) modulator methyl beta-carboline-3-carboxylate attenuates the behavioral effects of the positive GABA(A) modulators triazolam and pregnanolone in rhesus monkeys.
2001-11
Flumazenil improves cognitive and neuromotor emergence and attenuates shivering after halothane-, enflurane- and isoflurane-based anesthesia.
2001-11
Confluence of antianalgesic action of diverse agents through brain interleukin(1beta) in mice.
2001-11
Nutritional parameters modify muricidal behavior of male Wistar rats: preventive effects of amino acids and 4' Cl diazepam.
2001-10-26
Synergistic interaction of diazepam with 3',5'-cyclic adenosine monophosphate-elevating agents on rat aortic rings.
2001-10-05
Benzodiazepines in the intensive care unit.
2001-10
Benzodiazepine-GABA(A) receptor binding is very low in dysembryoplastic neuroepithelial tumor: a PET study.
2001-10
Prolonged vigabatrin treatment modifies developmental changes of GABA(A)-receptor binding in young children with epilepsy.
2001-10
[Tetraplegia in the course of coma from drug intoxication].
2001-10
[18F]Fluoroethylflumazenil: a novel tracer for PET imaging of human benzodiazepine receptors.
2001-10
Biodistribution, binding specificity and metabolism of [18F]fluoroethylflumazenil in rodents.
2001-10
A change in the density of [(3)H]flumazenil, but not [(3)H]muscimol binding, in Brodmann's Area 9 from subjects with bipolar disorder.
2001-10
2-Arylpyrazolo[1,5-a]pyrimidin-3-yl acetamides. New potent and selective peripheral benzodiazepine receptor ligands.
2001-10
Anxiolytic effect of Kami-Shoyo-San (TJ-24) in mice: possible mediation of neurosteroid synthesis.
2001-09-21
Vesicular neurotransmitter transporters in Huntington's disease: initial observations and comparison with traditional synaptic markers.
2001-09-15
Dose-dependent enhancement of in vivo GABA(A)-benzodiazepine receptor binding by isoflurane.
2001-09
The effects of flumazenil, Ro 154513 and beta-CCM on the behaviour of control and stressed mice in the staircase test.
2001-09
SPECT and neuropsychological performance in severe depression treated with ECT.
2001-09
Potency of positive gamma-aminobutyric acid(A) modulators to substitute for a midazolam discriminative stimulus in untreated monkeys does not predict potency to attenuate a flumazenil discriminative stimulus in diazepam-treated monkeys.
2001-09
Influence of benzodiazepine binding site ligands on fear-conditioned contextual memory.
2001-08-24
GABAergic and glutamatergic modulation of exploratory behavior in the dorsomedial hypothalamus.
2001-08-18
Increase in expression of the GABA(A) receptor alpha(4) subunit gene induced by withdrawal of, but not by long-term treatment with, benzodiazepine full or partial agonists.
2001-08-15
Benzodiazepines protect against ethanol-induced gastric mucosal damage in vitro.
2001-08
Neurophysiological effects of an extract of Eschscholzia californica Cham. (Papaveraceae).
2001-08
Different types of GABA(A) receptors may mediate the anticonflict and response rate-decreasing effects of zaleplon, zolpidem, and midazolam in squirrel monkeys.
2001-08
Diazepam increases the hypothalamic-pituitary-adrenocortical (HPA) axis activity by a cyclic AMP-dependent mechanism.
2001-08
Changes in mACh, NMDA and GABA(A) receptor binding after lateral fluid-percussion injury: in vitro autoradiography of rat brain frozen sections.
2001-08
The effects of benzodiazepines on human opioid receptor binding and function.
2001-08
High-dose flumazenil potentiates the hypnotic activity of propofol, but not that of thiopental, in ddY mice.
2001-08
Availability of antidotes at acute care hospitals in Ontario.
2001-07-10
A fluorescent receptor assay for benzodiazepines using coumarin-labeled desethylflumazenil as ligand.
2001-07-01
Disturbed benzodiazepine receptor function at the onset of temporal lobe epilepsy--lomanzenil-binding in de-novo TLE.
2001-07
Case report of pallido-pyramidal disease with supplementary motor area involvement.
2001-07
Hepatic Encephalopathy.
2001-07
Reversal of reserpine-induced vacuous chewing movements in rats by melatonin: involvement of peripheral benzodiazepine receptors.
2001-06-15
Visual event-related potentials in cirrhotic patients without overt encephalopathy: the effects of flumazenil.
2001-06
Melatonin enhances Th2 cell mediated immune responses: lack of sensitivity to reversal by naltrexone or benzodiazepine receptor antagonists.
2001-05
Comparison of N2O- and chlordiazepoxide-induced behaviors in the light/dark exploration test.
2001-04
Benzodiazepine receptor antagonists for acute and chronic hepatic encephalopathy.
2001
Voluntary self-poisoning as a cause of admission to a tertiary hospital internal medicine clinic in Piraeus, Greece within a year.
2001
Patents

Patents

04346030
7
04346036
7
04352818
7
JP2008201796A
1

Sample Use Guides

In Vivo Use Guide
Usual Adult Dose for Reversal of Sedation Initial dose: 0.2 mg IV one time over 15 seconds. Repeated doses: 0.2 mg may be given every minute until the desired level of consciousness is achieved. Maximum total dose 1 mg. Most patients respond to 0.6 to 1 mg.
Route of Administration: Intravenous
In Vitro Use Guide
Exposure (48 h) of human embryonic kidney (HEK) 293 cells stably expressing recombinant alpha1beta2gamma2S GABAA receptors to flumazenil (1 or 5 uM) in the presence of GABA (1 uM) enhanced the maximum number (Bmax) of [3H]flunitrazepam binding sites without affecting their affinity (Kd).
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:48:43 GMT 2025
Edited
by admin
on Mon Mar 31 17:48:43 GMT 2025
Record UNII
40P7XK9392
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ANEXATE
Preferred Name English
FLUMAZENIL
EP   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN   INN  
Official Name English
FLUMAZENIL [USAN]
Common Name English
RO-15-1788
Code English
FLUMAZENIL [MI]
Common Name English
FLUMAZEPIL
Common Name English
Flumazenil [WHO-DD]
Common Name English
MAZICON
Brand Name English
FLUMAZENIL [USP-RS]
Common Name English
FLUMAZENIL [VANDF]
Common Name English
Ethyl 8-fluoro-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate
Systematic Name English
RO-151788
Code English
FLUMAZENIL [MART.]
Common Name English
RO-151788000
Code English
NSC-759193
Code English
RO 15-1788/000
Code English
RO-1722
Code English
FLUMAZENIL [EP MONOGRAPH]
Common Name English
FLUMAZENIL [ORANGE BOOK]
Common Name English
LANEXAT
Brand Name English
FLUMAZENIL [USP MONOGRAPH]
Common Name English
ROMAZICON
Brand Name English
4H-IMIDAZO(1,5-A)(1,4)BENZODIAZEPINE-3-CARBOXYLIC ACID, 8-FLUORO-5,6-DIHYDRO-5-METHYL-6-OXO-, ETHYL ESTER
Common Name English
flumazenil [INN]
Common Name English
RO-15-1788/000
Code English
FLUMAZENIL [JAN]
Common Name English
RO-41-8157
Code English
Classification Tree Code System Code
WHO-ATC V03AB25
Created by admin on Mon Mar 31 17:48:44 GMT 2025 , Edited by admin on Mon Mar 31 17:48:44 GMT 2025
WHO-VATC QV03AB25
Created by admin on Mon Mar 31 17:48:44 GMT 2025 , Edited by admin on Mon Mar 31 17:48:44 GMT 2025
NCI_THESAURUS C1012
Created by admin on Mon Mar 31 17:48:44 GMT 2025 , Edited by admin on Mon Mar 31 17:48:44 GMT 2025
NDF-RT N0000175680
Created by admin on Mon Mar 31 17:48:44 GMT 2025 , Edited by admin on Mon Mar 31 17:48:44 GMT 2025
Code System Code Type Description
INN
5311
Created by admin on Mon Mar 31 17:48:44 GMT 2025 , Edited by admin on Mon Mar 31 17:48:44 GMT 2025
PRIMARY
RXCUI
4457
Created by admin on Mon Mar 31 17:48:44 GMT 2025 , Edited by admin on Mon Mar 31 17:48:44 GMT 2025
PRIMARY RxNorm
EVMPD
SUB07693MIG
Created by admin on Mon Mar 31 17:48:44 GMT 2025 , Edited by admin on Mon Mar 31 17:48:44 GMT 2025
PRIMARY
PUBCHEM
3373
Created by admin on Mon Mar 31 17:48:44 GMT 2025 , Edited by admin on Mon Mar 31 17:48:44 GMT 2025
PRIMARY
MERCK INDEX
m5436
Created by admin on Mon Mar 31 17:48:44 GMT 2025 , Edited by admin on Mon Mar 31 17:48:44 GMT 2025
PRIMARY Merck Index
SMS_ID
100000080704
Created by admin on Mon Mar 31 17:48:44 GMT 2025 , Edited by admin on Mon Mar 31 17:48:44 GMT 2025
PRIMARY
DAILYMED
40P7XK9392
Created by admin on Mon Mar 31 17:48:44 GMT 2025 , Edited by admin on Mon Mar 31 17:48:44 GMT 2025
PRIMARY
NCI_THESAURUS
C47534
Created by admin on Mon Mar 31 17:48:44 GMT 2025 , Edited by admin on Mon Mar 31 17:48:44 GMT 2025
PRIMARY
EPA CompTox
DTXSID2023064
Created by admin on Mon Mar 31 17:48:44 GMT 2025 , Edited by admin on Mon Mar 31 17:48:44 GMT 2025
PRIMARY
IUPHAR
4192
Created by admin on Mon Mar 31 17:48:44 GMT 2025 , Edited by admin on Mon Mar 31 17:48:44 GMT 2025
PRIMARY
RS_ITEM_NUM
1273808
Created by admin on Mon Mar 31 17:48:44 GMT 2025 , Edited by admin on Mon Mar 31 17:48:44 GMT 2025
PRIMARY
DRUG CENTRAL
1195
Created by admin on Mon Mar 31 17:48:44 GMT 2025 , Edited by admin on Mon Mar 31 17:48:44 GMT 2025
PRIMARY
WIKIPEDIA
FLUMAZENIL
Created by admin on Mon Mar 31 17:48:44 GMT 2025 , Edited by admin on Mon Mar 31 17:48:44 GMT 2025
PRIMARY
MESH
D005442
Created by admin on Mon Mar 31 17:48:44 GMT 2025 , Edited by admin on Mon Mar 31 17:48:44 GMT 2025
PRIMARY
ChEMBL
CHEMBL407
Created by admin on Mon Mar 31 17:48:44 GMT 2025 , Edited by admin on Mon Mar 31 17:48:44 GMT 2025
PRIMARY
CAS
78755-81-4
Created by admin on Mon Mar 31 17:48:44 GMT 2025 , Edited by admin on Mon Mar 31 17:48:44 GMT 2025
PRIMARY
USAN
W-44
Created by admin on Mon Mar 31 17:48:44 GMT 2025 , Edited by admin on Mon Mar 31 17:48:44 GMT 2025
PRIMARY
DRUG BANK
DB01205
Created by admin on Mon Mar 31 17:48:44 GMT 2025 , Edited by admin on Mon Mar 31 17:48:44 GMT 2025
PRIMARY
NSC
759193
Created by admin on Mon Mar 31 17:48:44 GMT 2025 , Edited by admin on Mon Mar 31 17:48:44 GMT 2025
PRIMARY
CHEBI
5103
Created by admin on Mon Mar 31 17:48:44 GMT 2025 , Edited by admin on Mon Mar 31 17:48:44 GMT 2025
PRIMARY
FDA UNII
40P7XK9392
Created by admin on Mon Mar 31 17:48:44 GMT 2025 , Edited by admin on Mon Mar 31 17:48:44 GMT 2025
PRIMARY
Related Record Type Details
GABAA RECEPTOR (RAT)
TARGET -> INHIBITOR
IC50
GABAA RECEPTOR
TARGET -> INHIBITOR
Has been used as an antidote in the treatment of benzodiazepine and Z-drug overdoses.[
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
Related Record Type Details
Structure of N-DESMETHYLFLUMAZENIL
METABOLITE -> PARENT
probably by cytochrome P450
Related Record Type Details
Structure of FLUMAZENIL DIONE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of DIMETHYLFORMAMIDE DIETHYLACETAL
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (TLC)
USP
Structure of DESFLUORO FLUMAZENIL
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of DESFLUORO HYDROXYFLUMAZENIL
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of FLUMAZENIL ACID
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of CHLOROFLUMAZENIL
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
Structure of FLUMAZENIL
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966